Answers are grounded in this paper and cite their sources.
The advancement of nanocarriers is crucial for improving drug delivery efficiency in nanomedicine. This study presents a novel epigallocatechin gallate (EGCG)-loaded graphene oxide-mesoporous silica nanoparticle (EGCG–GO–MSN) composite engineered for enhanced drug encapsulation and controlled release. Graphene oxide (GO) was synthesized using a modified Hummers’ method to introduce oxygenated functional groups, enhancing hydrophilicity and drug affinity. Mesoporous silica nanoparticles (MSN), prepared via the sol-gel method, offered a high surface area for drug entrapment. The hybrid GO-MSN system was developed through electrostatic interactions and hydrogen bonding, resulting in a structurally stable nanocomposite. EGCG, a potent polyphenol with limited aqueous solubility and a half-life of around 3.9 hrs, was effectively loaded into the nanocomposite to overcome its delivery challenges. Comprehensive characterization using FTIR, XRD, DSC, Raman spectroscopy, SEM, TEM and EDX confirmed successful synthesis, structural integrity and favorable morphology. Particle size analysis indicated nanoscale stability with uniform size distribution, optimal zeta potential, and low polydispersity index. In-vitro release studies demonstrated a biphasic profile with an initial burst (∼45% in 2 hrs), followed by sustained release (∼90 -93% over 9 hrs). These findings underscore the potential of GO-MSN nanocarriers in improving EGCG delivery and support their broader application in advanced pharmaceutical systems.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: